I have been active in the field of Tuberculosis Drug discovery for 7 years, first at the Novartis Institute for tropical Diseases (Singapore) and now at the Institut Pasteur-Korea (IP-K). As a contributor to the global pipeline, IP-K would like to be part of the stop TB partnership's WGND. We developed an unique screening platform for anti-TB drug discovery that can be beneficial for other organizations involved in TB R&D.